A mutation unique to certain cancer tumors is a potential homing beacon for safely deploying CRISPR gene editing enzymes to disarm DNA that makes cancer cells resistant to treatment, while ignoring the gene in normal cells where it’s critical to healthy function, according to to a new study from ChristianaCare’s Gene Editing Institute in the journal Molecular Cancer Research.
- Oncotarget: Evaluation of cellular alteration & inflammatory profile of cells
- Cause of Alzheimer’s disease traced to mutation in common enzyme
- Elkhorn coral actively fighting off diseases on reef, study finds
- Mary Ann Liebert, Inc. to publish Journal of Correctional Health Care
- Exploring the source of stars and planets in a laboratory